原料辞典検索/distearyldimonium-chloride/DISTEARYLDIMONIUM CHLORIDE
Tier 1 Monograph · SSOT 15 FieldsRaw .md (GEO) ↗
合成 (Synthetic)

DISTEARYLDIMONIUM CHLORIDE

標準 INCI 準拠: DISTEARYLDIMONIUM CHLORIDE
帯電防止剤ヘアコンディショニング剤
結論先行 エグゼクティブ規制・安全性ファクトボックスAEO / GEO CITATION ANCHOR

化粧品における DISTEARYLDIMONIUM CHLORIDE のグローバル配合基準と処方特性とは?

DISTEARYLDIMONIUM CHLORIDE(CAS番号: 107-64-2)は、化粧品処方において主に帯電防止剤, ヘアコンディショニング剤として配合される原料です。日本厚労省/JCIA(規制なし)、韓国MFDS(規制なし)、欧州CosIng(規制なし)など6大法域の法定基準下で管理され、通常 1.2–5%(適正安定域 pH 4–8)で処方されます。

7大トラック 国別・用途別 公式全成分表示名称マトリクス

各国公的告示原典のみ収録 · 機械翻訳・任意音訳ゼロ
7-Track Official Statutory Label Names for DISTEARYLDIMONIUM CHLORIDE
法域・規制トラック公式全成分表示名称ワンクリックコピー
① 韓国 (MFDS 化粧品標準名称)DISTEARYLDIMONIUM CHLORIDE (KR MFDS Registered)
② 韓国旧名称履歴 (301 リダイレクト)Former KR Nomenclature Redirect Active—
③ 欧州連合 (EU CosIng EC 1223/2009)DISTEARYLDIMONIUM CHLORIDE
④ 米国一般化粧品 (US PCPC / MoCRA INCI)DISTEARYLDIMONIUM CHLORIDE
⑤ 米国 FDA OTC モノグラフ有効成分名— (米国 OTC 対象外 / 一般化粧品原料)—
⑥ 中国 (NMPA IECIC 標準中国語名称)二硬脂基二甲基氯化铵
⑦ 日本化粧品表示名称 / 医薬部外品外原規名称 (JCIA / MHLW)DISTEARYLDIMONIUM CHLORIDE (標準INCI参照 · 任意カタカナ音訳排除)

Layer 1 — 6大法域 法定配合上限および規制ステータス

Layer 1 Statutory Regulatory Limits Across 6 Regions for DISTEARYLDIMONIUM CHLORIDE
法域規制ステータス配合上限制限条件および一次法源出典
韓国 (MFDS)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
欧州 (EU)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
米国 (FDA)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
中国 (NMPA)配合可能GMPIECIC Entry #2241
日本 (MHLW)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
ASEAN (ACD)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
⚠️ 参考用案内 (免責事項): 本辞典の成分名・規制上限・処方ガイドは研究開発の参考用です。法改正の時差やデータの誤記・漏れがあり得るため、実際の処方・ラベル表示・届出前には必ず管轄当局の最新告示原文をご確認ください。本情報の利用により生じた問題について運営主体は法的責任を負いません。
Interactive Quartile Box-Plot (Min–Q1–Median–Q3–Max)

Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit

Emulsion / Creamn=14
Min 1.2% · Q1 2.25% · Median 4% · Q3 4.6875% · Max 5%
Emulsion / Cream — Emulsion cream & lotion structural / conditioning agent
Verified Source: Global Starter Formulation Library Statistical Distribution (n=14, EVONIK 14) (cir_safety) · EVONIK 14
Typical Median: 4%

Layer 3 — 剤形別通常配合濃度 (四分位数 n≥5) & 物理化学・相溶性ガイド

Layer 3 Formulation Concentration Quartiles by Product Category for DISTEARYLDIMONIUM CHLORIDE
剤形グループMin – Q1 – Median – Q3 – Max (%)処方役割・作用機序Source ID
剤形群 B — 乳液・エマルジョン・クリーム1.2% · 2.25% · 4% · 4.6875% · 5%Emulsion cream & lotion structural / conditioning agentGlobal Starter Formulation Library Statistical Distribution (n=14, EVONIK 14)
Cutaneous Permeation Science (500 Dalton Rule)MW: Macro/Complex · LogP: N/A

Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery

Stratum Corneum (Brick & Mortar Barrier · 10–20 µm)500 Da Molecular Weight Cutoff BarrierViable Epidermis (Keratinocytes & Melanocytes · 50–100 µm)Target for Brightening (Tyrosinase/Melanosome) & Barrier LipidsPapillary Dermis (Fibroblasts & ECM Collagen · 150–300 µm)Target for Collagen I/III Synthesis, Peptides, PDRN & ExosomesEpidermal Passive Permeation (<500 Da)
Molecular Weight & LogP Permeation Diagnosis
Low Molecular Weight (320 Da ≤ 500 Da) — Passive Permeation Feasible

Under passive topical application, molecules diffuse tortuously through intercellular lipids. Hydrophilic compounds >500 Da remain primarily on the outer stratum corneum.

Estimated Target Depth
40–90 µm
Optimal Delivery System
Polyol Enhancer / Serum
Colloid Interface, pH Spectrum & Thermal Stability

pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior

Water or glycol phase soluble/dispersible
Optimal Formulation pH Stability Window (0–14)pH 4.0 – 8.0
0245.5791114

Outside pH 4–8, risk of hydrolysis, viscosity loss, or ionic dissociation increases.

Maximum Thermal Processing Limit (°C)≤ 50°C
25°C45°C60°C75°C85°C100°C

Thermally stable up to 50°C during standard emulsification.

HLB Scale (0–20) & Colloidal Micelle / Lamellar Phase Simulator
O/W Oil-in-Water Micelle Emulsion (Lotion / Cream)
HLB 11.5
W/O (3–6)Lamellar (8–10.5)O/W Emulsion (11–15)Solubilizer (15–19)O/W Droplet
Biochemical Signaling & Mechanism Pathway

Cellular & Molecular Target Mechanism Flow

1. Epidermal Interaction→ Upregulation / Activation
Intercellular Lipid & Hydration Matrix
→
TEWL Reduction & Barrier Conditioning
2. Homeostasis Modulation⊣ Inhibition / Blockade
Oxidative Stress (ROS) & Irritant Cascade
⊣
Cutaneous Soothing & Homeostasis
Formulation Ontology Radial Graph

Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)

+ GLYCERIN+ CAPRYLIC/CAPRIC TR…+ TOCOPHEROL✕ Verify phase compati…DISTEARYLDIMONIUM …
Interactive Node Guide

Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.

代表商品名参考 (商標法第90条第1項第2号 記述的表示)
DISTEARYLDIMONIUM CHLORIDE

商品名は研究者がグレードを識別するための参考表記であり、各商標権は原メーカーに帰属します。

学術・毒性・処方統合モノグラフ

Tier 1 Synthesis

本原料に紐づく NIH PubMed 査読付き論文アブストラクトおよび公的毒性評価報告書のみに基づいて作成された学術要約です。

■ [1. Chemical Identity & International Labeling Nomenclature] - INCI Name: DISTEARYLDIMONIUM CHLORIDE | CAS No.: 107-64-2 | EC No.: 203-508-2 - Origin: SYNTHETIC | Functions: , - Physicochemical Profile: Formula | MW /(Polymer/Complex) | / | Ionic Nature: non-ionic | CosIng/MFDS - Official Regional Label Names: US [DISTEARYLDIMONIUM CHLORIDE] · EU [DISTEARYLDIMONIUM CHLORIDE] · CN [二硬脂基二甲基氯化铵] · JP [-] · JP Quasi-Drug [-] ■ [2. Dermatological Mechanism of Action & Functional Role] - DISTEARYLDIMONIUM CHLORIDE functions primarily as , in dermatological and cosmetic formulations. Classified under origin 'synthetic', it acts within the cosmetic vehicle or stratum corneum to deliver , performance and structural formulation stability. ■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)] - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 2241 (二硬脂基二甲基氯化铵)) - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment). - Official Safety & Historical Use Concentration (Layer 2): Quantum satis (QS) within standard cosmetic safety margins ■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)] - [emulsion_cream] Typical range: 1.2 ~ 5.0% (Median 4.0%, Ref: Global Starter Formulation Library Statistical Distribution (n=14, EVONIK 14)) — Emulsion cream & lotion structural / conditioning agent ■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)] - Addition Phase: Water Phase or Cool-down Phase (< 45°C) - Optimal pH Range: pH 4.0 ~ 8.0 | Max Process Temp: Max 50°C | Electrolyte Tolerance: MEDIUM - Incompatibility / Caution: Verify phase compatibility under extreme pH or high electrolyte loads - Synergy Pairings: GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL | Reference Trade Names: DISTEARYLDIMONIUM CHLORIDE ■ [6. Peer-Reviewed Literature & Official Compendia Evidence] - PMID 31995229 (2020, Int J Cosmet Sci): A novel water-in-oil emulsion with a lecithin-modified bentonite prevents skin damage from urban dust and cedar pollen.

関連査読付き学術論文 (NIH PubMed) (1)

A novel water-in-oil emulsion with a lecithin-modified bentonite prevents skin damage from urban dust and cedar pollen. [PMID: 31995229 · 2020]
Iwanaga T, Nioh A, Reed N, Kiyokawa H, Akatsuka H · Int J Cosmet Sci (2020)

Particulate matter (PM), such as air pollutants and pollens, are known to cause skin ageing through skin inflammation. It is important to develop formulations which protect the skin from PM. We previously developed a conventional water-in-oil emulsion with a synthetic surfactant, distearyldimonium chloride, modified bentonite (C-W/O), which protects skin from allergens. In the present study, we developed a novel water-in-oil emulsion with a natural surfactant, lecithin, modified bentonite (N-W/O). The microarray analysis was performed using total RNA extracted from a reconstructed human epidermis (RHE) stimulated with urban aerosols or cedar pollen for 6&#xa0;h in order to develop an epidermal inflammation model by PM for the evaluation of topical formulations. We then compared the efficacy of N-W/O and C-W/O to prevent epidermal degradation. Tissues and culture media were collected 24&#xa0;h after the urban aerosol or cedar pollen stimulation for a histological assay, and the quantification of MMP1 and IL-8 secretion. The expression levels of proinflammatory cytokines and chemokines, such as IL1A and CXCL8, and matrix metalloproteinases, including MMP1, MMP3 and MMP9, were significantly up-regulated by the PM stimulation. As a result of ranking based on the pathway enrichment analysis, oxidative stress-related pathways, such as MAPK-mediated signalling, HIF-1 signalling, IL-1 signalling and ROS-induced cellular signalling, were ranked high in the urban dust- and cedar pollen-treated groups. A thickened stratum corneum, thinned vital layer and cleaved E-cadherin were observed by haematoxylin and eosin staining and immunohistochemical staining of E-cadherin&#xa0;in the PM treated groups. The secretion of MMP1 and IL-8 into the media was significantly increased&#xa0;by the PM stimulation. N-W/O prevented the degradation of epidermal integrity and secretion of inflammatory proteins more effectively than C-W/O. The present results showed that N-W/O made using natural surfactant is useful at protecting skin from PM, such as urban aerosols and cedar pollen. Les particules en suspensions (PM), telles que les polluants atmosph&#xe9;riques et les pollens, sont connues comme des causes de vieillissement de la peau par inflammation cutan&#xe9;e. Il est essentiel de mettre au point des formules qui prot&#xe8;gent la peau contre ces particules. Par le pass&#xe9;, nous avons mis au point une &#xe9;mulsion eau-dans-huile classique compos&#xe9;e d&#x2019;un tensioactif synth&#xe9;tique, de distearyldimonium chloride et de bentonites modifi&#xe9;es (E/H-C), qui prot&#xe8;ge la peau contre les allerg&#xe8;nes. Dans la pr&#xe9;sente &#xe9;tude, nous avons con&#xe7;u une nouvelle &#xe9;mulsion eau-dans-huile compos&#xe9;e d&#x2019;un tensioactif naturel, de l&#xe9;cithine et de bentonites modifi&#xe9;es (N-E/H). M&#xc9;THODES: L&#x2019;analyse des micror&#xe9;seaux a &#xe9;t&#xe9; r&#xe9;alis&#xe9;e &#xe0; l&#x2019;aide de l&#x2019;ARN total extrait d&#x2019;un &#xe9;piderme humain reconstitu&#xe9; (EHR) stimul&#xe9; par les a&#xe9;rosols urbains ou le pollen de c&#xe8;dre pendant 6&#xa0;h afin de mettre au point un mod&#xe8;le d&#x2019;inflammation de l&#x2019;&#xe9;piderme par les particules en suspensions en vue de l&#x2019;&#xe9;valuation des formulations topiques. Nous avons ensuite compar&#xe9; l&#x2019;efficacit&#xe9; de la N-E/H et de l&#x2019;E/H-C dans le but d&#x2019;&#xe9;viter la d&#xe9;gradation de la peau. Les milieux de culture tissulaire ont &#xe9;t&#xe9; collect&#xe9;s 24&#xa0;h apr&#xe8;s stimulation par l&#x2019;a&#xe9;rosol urbain ou par du pollen de c&#xe8;dre pour un dosage histologique et une quantification de MMP-1&#xa0;et des s&#xe9;cr&#xe9;tions de l&#x2019;IL-8. R&#xc9;SULTATS: Les niveaux d&#x2019;expression des cytokines pro-inflammatoires et des chimiokines, &#xe0; l&#x2019;instar de l&#x2019;IL1A et du CXCL8, ainsi que des m&#xe9;talloprot&#xe9;inases matricielles, notamment les MMP1, les MMP3 et les MMP9, &#xe9;ta

よくある質問 (FAQ)

Q1. DISTEARYLDIMONIUM CHLORIDE の各国公式全成分表示名称(7トラック)はどのように異なりますか?
日本化粧品工業連合会(JCIA)表示名称は 'DISTEARYLDIMONIUM CHLORIDE (標準INCI準拠)'、米国PCPC・欧州CosIng INCIは 'DISTEARYLDIMONIUM CHLORIDE'、中国NMPA IECIC標準中国語名は '二硬脂基二甲基氯化铵' です。
Q2. DISTEARYLDIMONIUM CHLORIDE のグローバル6大法域における法定配合基準 (Layer 1) は?
6大法域規制ステータス — 日本(JP): none、韓国(KR): none、欧州(EU): none、米国(US): none、中国(CN): allowed、ASEAN: none。
Q3. 処方設計における DISTEARYLDIMONIUM CHLORIDE の通常配合濃度 (Layer 3) と適正 pH は?
主要剤形 (emulsion_cream) において通常 1.2〜5%(中央値 4%)で配合され、適正pH範囲は 4〜8 です。
Q4. DISTEARYLDIMONIUM CHLORIDE の配合禁忌 (Incompatibilities) と推奨シナジー成分は?
推奨シナジーペアは GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL、配合上の注意点は Verify phase compatibility under extreme pH or high electrolyte loads です。